Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
16. Mai 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event
12. Mai 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
02. Mai 2023 07:00 ET
|
Plus Therapeutics Inc.
New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (186Re) obisbemeda radiotherapeutic AUSTIN, Texas, May 02, 2023 (GLOBE NEWSWIRE)...
Plus Therapeutics Announces Reverse Stock Split
28. April 2023 12:55 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
20. April 2023 16:05 ET
|
Plus Therapeutics Inc.
Plus completes Phase 1/Part A of the ReSPECT-LM trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc....
Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
19. April 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
18. April 2023 16:15 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases
18. April 2023 07:00 ET
|
Plus Therapeutics Inc.
The Company plans to meet with U.S. FDA to discuss next steps for the Phase 1/Part B trial in the third quarter of 2023 Expanded the number of active clinical trial sites by adding Northwestern...
Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023
12. April 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
28. März 2023 07:00 ET
|
Plus Therapeutics Inc.
Company also enrolling ReSPECT-GBM Phase 2 trial Presentation of data from Phase 1/2a and Phase 2 trials planned in 2023 AUSTIN, Texas, March 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc....